A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
Yunxin ChenSathish Kumar GopalakrishnanMelissa OoiRehena SultanaLi Hui LimNicholas Francis GrigoropoulosShin Yeu OngMingge Xunull nullWee-Joo ChngYeow Tee GohChandramouli NagarajanPublished in: Blood cancer journal (2021)